Verismo Therapeutics Activates its STAR-101 Clinical Trial to Evaluate Investigational Drug SynKIR-110
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
PCI’s Carter Caldwell Is Interviewed on Launching a Startup
PCI’s Carter Caldwell, program director for the Penn Medicine Co-Investment Program, discussed his entrepreneurial career and shared advice for others looking to start businesses.
Penn Today Highlights How Penn Research Powers Numerous FDA-approved Treatments
From CAR-T therapy to the mRNA covid-19 vaccine, the list of Penn-linked FDA approvals has been growing with each passing year.
SAFELab takes space at Pennovation Center
SAFELab is a research initiative focused on examining the ways in which youth of color navigate violence on and offline.
Penn Medicine Magazine Showcases Penn’s Drug Research and Development and Commercial Partnerships
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Technology to help Newborns in the NICU wins 2023 President’s Innovation Prize
Penn President Liz Magill awarded the 2023 President’s Innovation Prize toGabriella Daltoso, Sophie Ishiwari, Gabriela Cano, Caroline Amanda Magro, and Tifara Eliana Boyce for their project, Sonura.
Canberra IP and VL Navigator work together to improve the process of finding University available technologies on Inteum Technology Publisher
Canberra IP will now link to Visible Legacy (VL) Navigator to Search, Navigate, and Connect with context to facilitate and speed up communication with a university licensing office and inventors.
Philadelphia Business Journal Features Liz Magill and her Innovation Goals
In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy.
Philadelphia ranks as one of the top five most active regions for venture capital in 1Q
According to the latest Pitchbook-NVCA Venture Monitor report, the Greater Philadelphia area ranked fifth in the U.S. for the most closed venture capital deals in 2022 and the start of 2023.
REGENXBIO Receives FDA Fast Track Designation for its Novel Gene Therapy Candidate
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.